EP3517537A1 - Deuterated derivative of l-tetrahydropalmatine and medical use thereof - Google Patents
Deuterated derivative of l-tetrahydropalmatine and medical use thereof Download PDFInfo
- Publication number
- EP3517537A1 EP3517537A1 EP17861072.1A EP17861072A EP3517537A1 EP 3517537 A1 EP3517537 A1 EP 3517537A1 EP 17861072 A EP17861072 A EP 17861072A EP 3517537 A1 EP3517537 A1 EP 3517537A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- drug
- rats
- pharmaceutically acceptable
- acceptable salt
- addiction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical class C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 title abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 208000002193 Pain Diseases 0.000 claims description 10
- 230000036407 pain Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 206010013663 drug dependence Diseases 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 201000006145 cocaine dependence Diseases 0.000 claims description 3
- 208000029790 metamphetamine dependence Diseases 0.000 claims description 3
- 229940001470 psychoactive drug Drugs 0.000 claims description 3
- 239000004089 psychotropic agent Substances 0.000 claims description 3
- 230000000391 smoking effect Effects 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 2
- 230000000307 algesic effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 229960003299 ketamine Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 10
- 231100000252 nontoxic Toxicity 0.000 abstract description 5
- 230000003000 nontoxic effect Effects 0.000 abstract description 5
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 231100000304 hepatotoxicity Toxicity 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 37
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000000202 analgesic effect Effects 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 8
- 229960002085 oxycodone Drugs 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940093956 potassium carbonate Drugs 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 235000011181 potassium carbonates Nutrition 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 210000003497 sciatic nerve Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- DKBYSDUFSXFXMP-INIZCTEOSA-N (13as)-2,3,10-trimethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinolin-9-ol Chemical compound COC1=C(OC)C=C2[C@@H]3CC4=CC=C(OC)C(O)=C4CN3CCC2=C1 DKBYSDUFSXFXMP-INIZCTEOSA-N 0.000 description 2
- KNWVMRVOBAFFMH-HNNXBMFYSA-N (S)-scoulerine Chemical compound C1CN2CC(C(=C(OC)C=C3)O)=C3C[C@H]2C2=C1C=C(OC)C(O)=C2 KNWVMRVOBAFFMH-HNNXBMFYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029174 Nerve compression Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- JKPISQIIWUONPB-HNNXBMFYSA-N (-)-stepholidine Chemical group C1CN2CC(C(=C(O)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(O)=C2 JKPISQIIWUONPB-HNNXBMFYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-NKUIMNHHSA-N (13aS)-2,3,10-trimethoxy-9-(trideuteriomethoxy)-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound COC=1C(=CC=2CCN3CC=4C(=C(C=CC=4C[C@H]3C=2C=1)OC)OC([2H])([2H])[2H])OC AEQDJSLRWYMAQI-NKUIMNHHSA-N 0.000 description 1
- AEQDJSLRWYMAQI-DBHFXHLNSA-N (13aS)-2,3,9-trimethoxy-10-(trideuteriomethoxy)-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound COC=1C(=CC=2CCN3CC=4C(=C(C=CC=4C[C@H]3C=2C=1)OC([2H])([2H])[2H])OC)OC AEQDJSLRWYMAQI-DBHFXHLNSA-N 0.000 description 1
- AEQDJSLRWYMAQI-GUBGJCPWSA-N (13aS)-2,9,10-trimethoxy-3-(trideuteriomethoxy)-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound COC=1C(=CC=2CCN3CC=4C(=C(C=CC=4C[C@H]3C=2C=1)OC)OC)OC([2H])([2H])[2H] AEQDJSLRWYMAQI-GUBGJCPWSA-N 0.000 description 1
- AEQDJSLRWYMAQI-BHTYFQISSA-N (13aS)-3,10-dimethoxy-2,9-bis(trideuteriomethoxy)-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound COC1=CC=2CCN3CC=4C(=C(C=CC=4C[C@H]3C=2C=C1OC([2H])([2H])[2H])OC)OC([2H])([2H])[2H] AEQDJSLRWYMAQI-BHTYFQISSA-N 0.000 description 1
- AEQDJSLRWYMAQI-JBKGLDERSA-N (13aS)-3,9,10-trimethoxy-2-(trideuteriomethoxy)-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound COC1=CC=2CCN3CC=4C(=C(C=CC=4C[C@H]3C=2C=C1OC([2H])([2H])[2H])OC)OC AEQDJSLRWYMAQI-JBKGLDERSA-N 0.000 description 1
- AEQDJSLRWYMAQI-MFVZUYHWSA-N (13aS)-3,9-dimethoxy-2,10-bis(trideuteriomethoxy)-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound COC1=CC=2CCN3CC=4C(=C(C=CC=4C[C@H]3C=2C=C1OC([2H])([2H])[2H])OC([2H])([2H])[2H])OC AEQDJSLRWYMAQI-MFVZUYHWSA-N 0.000 description 1
- DIHXHTWYVOYYDC-INIZCTEOSA-N (13as)-2,3,9-trimethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinolin-10-ol Chemical group C1CN2CC(C(=C(O)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 DIHXHTWYVOYYDC-INIZCTEOSA-N 0.000 description 1
- BMCZTYDZHNTKPR-INIZCTEOSA-N (13as)-2,9,10-trimethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinolin-3-ol Chemical group C1C2=CC=C(OC)C(OC)=C2CN2[C@@H]1C(C=C(C(=C1)O)OC)=C1CC2 BMCZTYDZHNTKPR-INIZCTEOSA-N 0.000 description 1
- KDFKJOFJHSVROC-INIZCTEOSA-N (S)-tetrahydrocolumbamine Chemical group C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(O)=C2 KDFKJOFJHSVROC-INIZCTEOSA-N 0.000 description 1
- 0 *Oc(ccc(C1)c2CN(CC3)[C@]1c(cc1O*)c3cc1O*)c2O* Chemical compound *Oc(ccc(C1)c2CN(CC3)[C@]1c(cc1O*)c3cc1O*)c2O* 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229930189907 rotundine Natural products 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- the present disclosure relates to a novel deuterated derivative of L-tetrahydropalmatine or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound as active ingredient, and a use of the derivative or a pharmaceutically acceptable salt thereof in the preparation of psychotropic drug.
- L-tetrahydropalmatine also known as rotundine, which is an alkaloid extracted from dried tubers of the plant Corydalis, a member of the poppy family, having various therapeutic effects such as sedation, hypnosis and analgesia, clinically useful in the treatment of headache, menstrual pain and insomnia.
- L-tetrahydropalmatine has better analgesic effects on neuropathic pain (NPP), inflammatory pain, cancer-induced pain and antitumor drug-induced pain. Taking L-tetrahydropalmatine for long periods of time does not lead to addiction, and has better effect on overcoming cocaine addiction, methamphetamine addiction, opioid or drug addiction, alcohol addiction, smoking addition, etc.
- L-tetrahydropalmatine leads to cardiac side effects such as reducing blood pressure, slowing heart rate, etc. It can also cause hepatotoxicity such as elevated transaminases, etc. Moreover, great individual differences in the effects of L-tetrahydropalmatine cause the uncontrollability of safety and efficacy of drugs.
- the present disclosure relates to novel deuterated derivatives of L-tetrahydropalmatine. These deuterated derivatives not only markedly improve pharmacological effects, but also significantly reduce cardiac side effects, hepatotoxicity, and remarkably decrease individual differences.
- each R1, R2, R3, and R4 is independently selected from methyl (-CH 3 ) and trideuteromethyl (-CD 3 ), at least one of R1, R2, R3, and R4 is selected from trideuteromethyl (-CD 3 ).
- the present disclosure also provides a pharmaceutical composition containing the compound of Formula I, for example, the compound of Formula I 1 , I 2 , I 3 , I 4 , I 5 , I 6 or I 7 , or a non-toxic pharmaceutically acceptable salt thereof as an active ingredient, and a suitable excipient.
- the pharmaceutical compositions may be solutions, tablets, capsules or injections; and the pharmaceutical compositions may be administered by injection or administered orally.
- the present disclosure also provides the use of the compound of Formula I or a non-toxic pharmaceutically acceptable salt thereof in the preparation of psychotropic drug.
- the compound of Formula I for example, is selected from Formula I 1 , I 2 , I 3 , I 4 , I 5 , I 6 or I 7 .
- the present disclosure also provides the use of the compound of Formula I or a non-toxic pharmaceutically acceptable salt thereof in the preparation of drug for the treatment of an algesic disease, such as inflammation-induced pain, cancer-induced pain, and antitumor drug-induced pain.
- an algesic disease such as inflammation-induced pain, cancer-induced pain, and antitumor drug-induced pain.
- the compound is selected from Formula I 1 , I 2 , I 3 , I 4 , I 5 , I 6 or I 7 .
- the present disclosure also provides the use of the compound of Formula I or a non-toxic pharmaceutically acceptable salt thereof in the preparation of drug for the treatment of an addictive disease, such as cocaine addiction, methamphetamine addiction, opioid or drug addiction, alcohol addiction, smoking addiction, ketamine addiction.
- an addictive disease such as cocaine addiction, methamphetamine addiction, opioid or drug addiction, alcohol addiction, smoking addiction, ketamine addiction.
- the compound is selected from Formula I 1 , I 2 , I 3 , I 4 , I 5 , I 6 or I 7 .
- the soli d was filtered off and the filtrate was evaporated to dryness under reduced pressure, and then separated by silica gel column chromatography, eluted wit h dichloromethane: methanol (10:1). The desired component was collected a nd evaporated to dryness under reduced pressure to give 130 mg of I 1 .
- i-1 was replaced with (13a S)-2,3,9-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-10-ol (i-2), which reacted with CD 3 I in the presence of potassium carbonate.
- the obtained mixture was separated by silica gel column chromatography to give 105 mg of I 2 .
- i-1 was replaced with (13a S)-3,9,10-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2-ol (i-3), which reacted with CD 3 I in the presence of potassium carbonate.
- the obtained mixture was separated by silica gel column chromatography to give 85 mg of I 3 .
- i-1 was replaced with (13a S)-2,9,10-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-3-ol (i-4), which reacted with CD 3 I in the presence of potassium carbonate.
- the obtained mixture was separated by silica gel column chromatography to give 92 mg of I 4 .
- i-5 was replaced with (13a S)-3,9-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,10-diol (i-6), which reacted with CD 3 I in the presence of potassium carbonate.
- the obtained mixture was separated by silica gel column chromatography to give 100 mg of I 6 .
- SD rats male, weight 160-180 g were randomly divided into groups with 6 rats in each group. After the rats were intragastrically administered different doses separately, they were placed in PVC observation boxes for habituation. After 30 min, the rats were injected subcutaneously with 20 ⁇ L of 2.7% formalin solution into the plantar surface of the left hind paws, and quickly put back in the PVC observation boxes for observation. The length of time the rats spent licking the injected-formalin paws at the early response (0-5 min, phase I) and the late response (15-30 min, Phase II) was recorded, and the analgesic activities of the test compounds were evaluated according to the length of time the rats spent licking during the period of observation. The experimental data were expressed as mean ⁇ standard deviation.
- Table 1 Analgesic effects of intragastric administration in a rat formalin model Drug Dose (mg/kg) Reaction time for phase I (sec) Reaction time for phase II (sec) Drug Dose (mg/kg) Reaction time for phase I (sec) Reaction time for phase II (sec) Solvent 79.3 ⁇ 10.7 218.7 ⁇ 12.7 I 4 20 90.3 ⁇ 29.0 151.2 ⁇ 31.6 40 61.5 ⁇ 36.6 74.3 ⁇ 38.0 THP 20 86.8 ⁇ 37.3 185.2 ⁇ 39.7 I 5 20 85.8 ⁇ 28.0 112.7 ⁇ 29.2* 40 40.6 ⁇ 28.3* 97.5 ⁇ 33.6* 40 53.4 ⁇ 23.5* 66.5 ⁇ 27.6** I 1 20 82.4 ⁇ 33.2 194.0 ⁇ 35.7 I 6 20 41.9 ⁇ 9.2** 66.7 ⁇ 8.7** 40 42.6 ⁇ 45.0* 92.7 ⁇ 25.1* 40 38.6 ⁇ 9.4**
- SD rats male, weight 160-180 g were anesthetized using sodium pentobarbital (40 mg/kg), of which the sciatic nerves were separated in the middle segment of the right hind limbs.
- the sciatic nerve was separated from the surrounding tissue using a sterile glass hook.
- Four rings were loosely ligated with sterile chrome gut (No. 4, 0.15 mm in diameter) by an interval of 1 to 2 mm.
- the rats were placed in a cage with cork dust. In the sham surgery group, the sciatic nerve was only exposed, and the other treatments were the same as described above.
- the rats after surgery were placed in a metal cage.
- the footpads of the rats were stimulated with different weights of fiber filaments with stimulus intervals of 5 seconds, until the fiber filament was found that elicits four to six foot-lifting reactions in rats during 10 stimulations.
- the weight of the filament was recorded and set to be the threshold (in g). Meanwhile, the number of foot-lifting response to the 10 stimulations of the fiber filaments of different weights was recorded, and the highest threshold was set at 26 g.
- Analgesic percent % pain theshold after drug treatment ⁇ pain threshold before drug treatment / maximal analgesia threshold ⁇ pain thershold before drug treatment ⁇ % .
- Table 2 Analgesic effects of intragastric administration in a rat chronic sciatic nerve compression neuralgia model Drug Dose (mg/kg) Analgesic percent (%) Drug Dose (mg/kg) Analgesic percent (%) THP 20 27.41 I 5 20 39.40 40 68.36 40 67.56 I 2 20 59.00 I 6 20 63.80 40 68.86 40 69.12 I 3 20 44.80 I 7 20 70.67 40 68.67 40 73.53
- SD rats male, weight 160-180 g were placed in conditioned place preference (CPP) training boxes, where the partition door between the boxes was open. Time the rats spent in each of the boxes was recorded within 15 min in order to determine the natural tendency of the rats. The rats were then randomly divided into groups with 10 rats in each group according to the amount of time spent in the white box.
- the white box was a drug box, and the black box was a box with the absence of the drug.
- the rats were injected subcutaneously with oxycodone (2.5 mg/kg, s.c.) or saline, and immediately placed in the white box or the black box to be trained for 45 minutes, once a day for 9 consecutive days.
- SD rats male, weight 160-180 g were fasted for 12 hours before administration but had free access to drinking water.
- the rats were randomly divided into groups. They were anesthetized with an intraperitoneal injection of 50 - 60 mg/kg dose of sodium pentobarbital. Each rat was fixed on the back on the surgical table. The skin was cut from the center of the neck, and an incision of about 2.5 cm was made. The subcutaneous tissue and the median muscle were separated; the trachea was fully exposed; and the endotracheal intubation was performed. The subcutaneous tissue was separated from front to back on the right side; the right common carotid artery, the vagus nerve and the sympathetic nerve were exposed; and the carotid artery cannulation was performed.
- the endotracheal tube and the carotid artery cannula were respectively connected to a respiration transducer and a blood pressure transducer, and then connected to a multifunctional physiological recorder.
- the rats were intragastrically administrated.
- Heart rate and blood pressure were measured at different time points after administration. The results are shown in Tables 4 and 5, respectively.
- Male Wistar rats were randomly divided into groups with 10 rats in each group and weighed. A certain concentration of a test sample was ground and suspended in a 0.5% sodium carboxymethyl cellulose solution. The sodium carboxymethyl cellulose suspension containing 40 mg/kg of the test compound and a blank sodium carboxymethyl cellulose suspension as a control were intragastrically administered, once a day for 14 consecutive days. After the last administration, the rats were fasted but had free access to drinking water for 12 hours, and then anesthetized. Their blood samples were obtained from the abdominal aortas.
Abstract
Description
- The present disclosure relates to a novel deuterated derivative of L-tetrahydropalmatine or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound as active ingredient, and a use of the derivative or a pharmaceutically acceptable salt thereof in the preparation of psychotropic drug.
- L-tetrahydropalmatine (THP), also known as rotundine, which is an alkaloid extracted from dried tubers of the plant Corydalis, a member of the poppy family, having various therapeutic effects such as sedation, hypnosis and analgesia, clinically useful in the treatment of headache, menstrual pain and insomnia.
- Recent studies have found that L-tetrahydropalmatine has better analgesic effects on neuropathic pain (NPP), inflammatory pain, cancer-induced pain and antitumor drug-induced pain. Taking L-tetrahydropalmatine for long periods of time does not lead to addiction, and has better effect on overcoming cocaine addiction, methamphetamine addiction, opioid or drug addiction, alcohol addiction, smoking addition, etc.
- However, L-tetrahydropalmatine leads to cardiac side effects such as reducing blood pressure, slowing heart rate, etc. It can also cause hepatotoxicity such as elevated transaminases, etc. Moreover, great individual differences in the effects of L-tetrahydropalmatine cause the uncontrollability of safety and efficacy of drugs.
- The present disclosure relates to novel deuterated derivatives of L-tetrahydropalmatine. These deuterated derivatives not only markedly improve pharmacological effects, but also significantly reduce cardiac side effects, hepatotoxicity, and remarkably decrease individual differences.
-
-
- The present disclosure also provides a pharmaceutical composition containing the compound of Formula I, for example, the compound of Formula I1, I2, I3, I4, I5, I6 or I7, or a non-toxic pharmaceutically acceptable salt thereof as an active ingredient, and a suitable excipient. The pharmaceutical compositions may be solutions, tablets, capsules or injections; and the pharmaceutical compositions may be administered by injection or administered orally.
- The present disclosure also provides the use of the compound of Formula I or a non-toxic pharmaceutically acceptable salt thereof in the preparation of psychotropic drug. The compound of Formula I, for example, is selected from Formula I1, I2, I3, I4, I5, I6 or I7.
- Furthermore, the present disclosure also provides the use of the compound of Formula I or a non-toxic pharmaceutically acceptable salt thereof in the preparation of drug for the treatment of an algesic disease, such as inflammation-induced pain, cancer-induced pain, and antitumor drug-induced pain. For example, the compound is selected from Formula I1, I2, I3, I4, I5, I6 or I7.
- Furthermore, the present disclosure also provides the use of the compound of Formula I or a non-toxic pharmaceutically acceptable salt thereof in the preparation of drug for the treatment of an addictive disease, such as cocaine addiction, methamphetamine addiction, opioid or drug addiction, alcohol addiction, smoking addiction, ketamine addiction. For example, the compound is selected from Formula I1, I2, I3, I4, I5, I6 or I7.
- The present disclosure will be further illustrated with the following examples; however, the scope of the disclosure is not limited to the examples described below. Those skilled in the art will appreciate that various changes and modifications to the examples can be made without departing from the spirit and scope of the disclosure.
-
- 341 mg (1 mmol) of (13a S)-2,3,10-trimethoxy-6,8,13,13a-tetrahydro-5H -isoquinolino[2,1-b]isoquinoline-9-ol (i-1) was added to 5 ml of dimethylform amide and dissolved under stirring; then 280 mg (2 mmol) of potassium car bonate was added, and 290 mg (2 mmol) of CD3I was added dropwise und er stirring. The reaction mixture was stirred at 50 °C for 15 hours. The soli d was filtered off and the filtrate was evaporated to dryness under reduced pressure, and then separated by silica gel column chromatography, eluted wit h dichloromethane: methanol (10:1). The desired component was collected a nd evaporated to dryness under reduced pressure to give 130 mg of I1. 1H-NMR (400MHz, CDCl3): 6.83 (s, 1H), 6.78 (d, 1H), 6.71 (d, 1H), 6.65 (s, 1H), 4.32 (d, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.81 (s, 1H), 3.59-3.50 (m, 2 H), 3.24 (dd, 1H), 3.21-3.10 (m, 2H), 2.83 (dd, 1H), 2.70-2.65 (m, 2H).
-
- Referring to Example 1, i-1 was replaced with (13a S)-2,3,9-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-10-ol (i-2), which reacted with CD3I in the presence of potassium carbonate. The obtained mixture was separated by silica gel column chromatography to give 105 mg of I2. 1H-NMR (400MHz, CDCl3): 6.81 (s, 1H), 6.79 (d, 1H), 6.72 (d, 1H), 6.64 (s, 1H), 4.30 (d, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.74 (s, 1H), 3.60-3.50 (m, 2H), 3.25 (dd, 1H), 3.20-3.10 (m, 2H), 2.81 (dd, 1H), 2.71-2.65 (m, 2H).
-
- Referring to Example 1, i-1 was replaced with (13a S)-3,9,10-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2-ol (i-3), which reacted with CD3I in the presence of potassium carbonate. The obtained mixture was separated by silica gel column chromatography to give 85 mg of I3. 1H-NMR (400MHz, CDCl3): 6.86 (s, 1H), 6.79 (d, 1H), 6.75 (d, 1H), 6.68 (s, 1H), 4.35 (d, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.61 (s, 1H), 3.55-3.50 (m, 2H), 3.22 (dd, 1H), 3.08-3.10 (m, 2H), 2.84 (dd, 1H), 2.70-2.65 (m, 2H).
-
- Referring to Example 1, i-1 was replaced with (13a S)-2,9,10-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-3-ol (i-4), which reacted with CD3I in the presence of potassium carbonate. The obtained mixture was separated by silica gel column chromatography to give 92 mg of I4. 1H-NMR (400MHz, CDCl3): 6.90 (s, 1H), 6.82 (d, 1H), 6.75 (d, 1H), 6.65 (s, 1H), 4.38 (d, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.68 (s, 1H), 3.56-3.51 (m, 2H), 3.25 (dd, 1H), 3.22-3.13 (m, 2H), 2.82 (dd, 1H), 2.71-2.68 (m, 2H).
-
- 327 mg (1 mmol) of (13a S)-3,10-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,9-diol (i-5) was added to 5 ml of dimethylformamide and dissolved under stirring; then 560 mg (4 mmol) of potassium carbonate was added, and 435 mg (3 mmol) of CD3I was added dropwise under stirring. The reaction mixture was stirred at 50 °C for 15 hours. The solid was filtered off and the filtrate was evaporated to dryness under reduced pressure, then separated by silica gel column chromatography and eluted with dichloromethane: methanol (10:1). The desired component was collected and evaporated to dryness under reduced pressure to give 115 mg of I5. 1H-NMR (400MHz, CDCl3): 6.88 (s, 1H), 6.77 (d, 1H), 6.73 (d, 1H), 6.61 (s, 1H), 4.32 (d, 1H), 3.87 (s, 3H), 3.80 (s, 1H), 3.52-3.50 (m, 2H), 3.21 (dd, 1H), 3.17-3.10 (m, 2H), 2.80 (dd, 1H), 2.68-2.63 (m, 2H).
-
- Referring to Example 5, i-5 was replaced with (13a S)-3,9-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,10-diol (i-6), which reacted with CD3I in the presence of potassium carbonate. The obtained mixture was separated by silica gel column chromatography to give 100 mg of I6. 1H-NMR (400MHz, CDCl3): 6.83 (s, 1H), 6.78 (d, 1H), 6.71 (d, 1H), 6.65 (s, 1H), 4.32 (d, 1H), 3.88 (s, 3H), 3.81 (s, 1H), 3.59-3.50 (m, 2H), 3.24 (dd, 1H), 3.21-3.10 (m, 2H), 2.83 (dd, 1H), 2.70-2.65 (m, 2H).
-
- After 60g of diethylene glycol was added into in a 100mL reaction flask and stirred under nitrogen flow, 7g of potassium hydroxide was added. When the temperature was raised to 80 °C, another portion of 7g potassium hydroxide was added. After all of potassium hydroxide was dissolved and the temperature was raised to 210 °C, the water was removed. When the temperature was constant, 3.55 g (10 mmol) of L-tetrahydropalmatine was added and heated at 205-210 °C for 1.5 h. The reaction mixture was then poured into crushed ice, and neutralized to pH 8-9 with solid ammonium chloride to afford a solid precipitate. The precipitated solid was filtered, separated by silica gel column chromatography and eluted with dichloromethane: methanol (2:1). The desired component was collected and evaporated to dryness under reduced pressure to give 1.1 g of i-7.
- 900 mg (3 mmol) of i-7 was added to 10 ml of dimethylformamide and dissolved under stirring; then 2.0 g (15 mmol) of potassium carbonate was added, and 2.2 g (15 mmol) of CD3I was added dropwise under stirring. The reaction mixture was stirred at 50 °C for 15 hours. The solid was filtered off and the filtrate was evaporated to dryness under reduced pressure, then separated by silica gel column chromatography and eluted with dichloromethane: methanol (10:1). The desired component was collected and evaporated to dryness under reduced pressure to give 120 mg of I7. 1H-NMR (400MHz, CDCl3): 6.87 (s, 1H), 6.75 (d, 1H), 6.70 (d, 1H), 6.61 (s, 1H), 4.30 (d, 1H), 3.61-3.50 (m, 2H), 3.23 (dd, 1H), 3.17-3.05 (m, 2H), 2.81 (dd, 1H), 2.72-2.67 (m, 2H).
- SD rats (male, weight 160-180 g) were randomly divided into groups with 6 rats in each group. After the rats were intragastrically administered different doses separately, they were placed in PVC observation boxes for habituation. After 30 min, the rats were injected subcutaneously with 20 µL of 2.7% formalin solution into the plantar surface of the left hind paws, and quickly put back in the PVC observation boxes for observation. The length of time the rats spent licking the injected-formalin paws at the early response (0-5 min, phase I) and the late response (15-30 min, Phase II) was recorded, and the analgesic activities of the test compounds were evaluated according to the length of time the rats spent licking during the period of observation. The experimental data were expressed as mean ± standard deviation. The shorter the licking time, the better the analgesic effect of the compound. The results are shown in Table 1:
Table 1 Analgesic effects of intragastric administration in a rat formalin model Drug Dose (mg/kg) Reaction time for phase I (sec) Reaction time for phase II (sec) Drug Dose (mg/kg) Reaction time for phase I (sec) Reaction time for phase II (sec) Solvent 79.3±10.7 218.7±12.7 I4 20 90.3±29.0 151.2±31.6 40 61.5±36.6 74.3±38.0 THP 20 86.8±37.3 185.2±39.7 I5 20 85.8±28.0 112.7±29.2* 40 40.6±28.3* 97.5±33.6* 40 53.4±23.5* 66.5±27.6** I1 20 82.4±33.2 194.0±35.7 I6 20 41.9±9.2** 66.7±8.7** 40 42.6±45.0* 92.7±25.1* 40 38.6±9.4** 40.3±9.0** I2 20 82.1±16.3 64.5±19.5** I7 20 45.2±9.9** 58.2±12.5** 40 41.0±10.7 46.5±16.0** 40 35.7±9.0** 35.9±13.6** I3 20 79.6±31.3 126.3±29.6 40 45.1±29.4 72.3±37.8** Compared with solvent group, * P<0.05, ** P<0.01. - SD rats (male, weight 160-180 g) were anesthetized using sodium pentobarbital (40 mg/kg), of which the sciatic nerves were separated in the middle segment of the right hind limbs. In the anterior segment of the sciatic nerve to be bifurcated, the sciatic nerve was separated from the surrounding tissue using a sterile glass hook. Four rings were loosely ligated with sterile chrome gut (No. 4, 0.15 mm in diameter) by an interval of 1 to 2 mm. Topically sprinkled with penicillin powder. The muscle tissue and skin were sutured. The rats were placed in a cage with cork dust. In the sham surgery group, the sciatic nerve was only exposed, and the other treatments were the same as described above. The rats after surgery were placed in a metal cage. The footpads of the rats were stimulated with different weights of fiber filaments with stimulus intervals of 5 seconds, until the fiber filament was found that elicits four to six foot-lifting reactions in rats during 10 stimulations. The weight of the filament was recorded and set to be the threshold (in g). Meanwhile, the number of foot-lifting response to the 10 stimulations of the fiber filaments of different weights was recorded, and the highest threshold was set at 26 g.
- 5-6 rats in each group were intragastrically administered and the pain thresholds were measured 1 hour after administration. Statistical analysis of the thresholds was performed using non-parametric Wilcoxon 2-Sample Test and Kruskal-Wallis Test, and the data was analyzed with SASS data processing software.
- The experimental results are shown in Table 2.
Table 2 Analgesic effects of intragastric administration in a rat chronic sciatic nerve compression neuralgia model Drug Dose (mg/kg) Analgesic percent (%) Drug Dose (mg/kg) Analgesic percent (%) THP 20 27.41 I5 20 39.40 40 68.36 40 67.56 I2 20 59.00 I6 20 63.80 40 68.86 40 69.12 I3 20 44.80 I7 20 70.67 40 68.67 40 73.53 - SD rats (male, weight 160-180 g) were placed in conditioned place preference (CPP) training boxes, where the partition door between the boxes was open. Time the rats spent in each of the boxes was recorded within 15 min in order to determine the natural tendency of the rats. The rats were then randomly divided into groups with 10 rats in each group according to the amount of time spent in the white box. The white box was a drug box, and the black box was a box with the absence of the drug. After intragastric administration with a test compound for 40 minutes, the rats were injected subcutaneously with oxycodone (2.5 mg/kg, s.c.) or saline, and immediately placed in the white box or the black box to be trained for 45 minutes, once a day for 9 consecutive days. On the 10th day, the rats were placed in the training boxes with the partition door open. The time the rats spent in the white box was recorded within 15 minutes to evaluate effects on place preference in the rats. The experimental results are shown in Table 3.
Table 3 Inhibition of oxycodone-induced place preference in rats Drug Test dose (mg/kg) Time spent in the drug box (Mean ± S, s) Solvent 112.11±32.23 oxycodone + saline 365.02±23.06 oxycodone + THP 10 253.23±77.14 20 157.04±60.6** oxycodone + I2 10 193.94±44.3* 20 140.59±28.52** oxycodone + I6 10 183.27±33.97* 20 129.35±23.66** oxycodone + I7 10 154.32±21.38** 20 135.40±25.09** Compared with solvent group, * P<0.05, ** P<0.01. - SD rats (male, weight 160-180 g) were fasted for 12 hours before administration but had free access to drinking water. The rats were randomly divided into groups. They were anesthetized with an intraperitoneal injection of 50 - 60 mg/kg dose of sodium pentobarbital. Each rat was fixed on the back on the surgical table. The skin was cut from the center of the neck, and an incision of about 2.5 cm was made. The subcutaneous tissue and the median muscle were separated; the trachea was fully exposed; and the endotracheal intubation was performed. The subcutaneous tissue was separated from front to back on the right side; the right common carotid artery, the vagus nerve and the sympathetic nerve were exposed; and the carotid artery cannulation was performed. Finally, the endotracheal tube and the carotid artery cannula were respectively connected to a respiration transducer and a blood pressure transducer, and then connected to a multifunctional physiological recorder. At 30 minutes after surgery, the rats were intragastrically administrated. Heart rate and blood pressure were measured at different time points after administration. The results are shown in Tables 4 and 5, respectively.
Table 4 Effects on blood pressure in rats Drug Dose (mg/kg) Blood pressure(mmHg) 0 30 60 90 120 180 Solvent 114.0±11.4 112.3±10.3 109.2±8.8 109.3±9.0 118.6±12.6 115.0±10.6 THP 20 111.5±11.5 109.4±20.6 105.00±28.21 105.1±20.0 112.7±19.3 113.3±18.3 40 114.2±14.6 98.0±30.1 81.63±28.8* 79.00±28.2* 91.6±24.7* 97.3±14.5 I2 20 113.1±15.7 113.4±17.3 101.5±27.46 102.25±21.6 113.1±14.2 102.3±7.6 40 114.6±19.4 95.5±15.9* 82.5±19.8* 92.8±18.6* 110.5±15.5 100.0±17.8 I6 20 115.6±21.9 108.5±10.75 102.0±11.4 104.7±10.70 110.5±6.8 106.5±13.7 40 111.0±21.4 95.4±14.5* 83.5±10.30* 85.2±8.0* 110.00±11.6 109.5±14.1 I7 20 112.6±27.5 103.4±11.7 104.2±9.8 102.6±7.2 114.1±11.3 135.3±15.6 40 113.0±11.4 92.4±.10.4* 83.5±7.2* 82.6±6.5* 95.3±9.5* 101.8±8.1 Compared with solvent group, * P<0.05, ** P<0.01. Table 5 Effects on heart rate in rats Drug Dose (mg/kg ) Heart rate (BTM) 0 30 60 90 120 180 Solvent 407.1±34.2 401.3±32.3 409.5±31.6 406.8±20.1 398.8±28.3 412.0±22.2 THP 20 399.3±32.6 377.1±52.3 387.3±50.5 399.8±60.7 408.8±55.9 429.8±25.5 40 391.8±32.9 372.1±46.5 329.0±63.2* 340.0±71.4* 372.0±64.6* 400.0±30.5 I2 20 400.8±32.1 378.3±30.3 384.6±48.2 388.0±21.4 402.5±59.3 407.0±36.5 40 409.2±41.7 390.7±41.7 319.7±57.2* 353.8±66.7* 378.0±47.6* 407.0±42.6 I6 20 407.1±43.4 400.2±29.4 401.0±28.47 403.0±30.2 396.7±36.3 402.5±28.8 40 414.1±37.6 375.8±29.3 362.8±20.7* 367.2±27.0* 393.5±34.6 380.8±30.5 I7 20 401.5±32.1 380.8±33.4 389.5±26.6 405.3±31.0 391.0±24.9 398.5±28.8 40 407.9±29.5 366.8±27.7 332.6±24.9* 343.2±21.0* 356.7±25.8* 362.0±32.1 Compared with solvent group, * P<0.05, ** P<0.01. - Male Wistar rats were randomly divided into groups with 10 rats in each group and weighed. A certain concentration of a test sample was ground and suspended in a 0.5% sodium carboxymethyl cellulose solution. The sodium carboxymethyl cellulose suspension containing 40 mg/kg of the test compound and a blank sodium carboxymethyl cellulose suspension as a control were intragastrically administered, once a day for 14 consecutive days. After the last administration, the rats were fasted but had free access to drinking water for 12 hours, and then anesthetized. Their blood samples were obtained from the abdominal aortas. According to SOPB093 "Standard Operating Procedures for Serum Preparation" in National Beijing Center for Drug Safety Evaluation and Research, serum was prepared for the determination of blood biochemical and immunological indicators; according to SOPB032 "Preparation of vacuum tubes with EDTA anticoagulation ", EDTA anticoagulation was prepared for the general blood routine tests.
- The results showed that weight gain and food consumption in the animals in each drug group were lower than those in the solvent control group, but there was no statistical difference. The test results of 14 hematological indices and 15 biochemical blood plasma indicators showed that there was a significant increase in plasma ALT and AST in Rotundine group, I2 and I6 groups, and no significant difference between I7 group and the control group in plasma ALT and AST. All other indicators were within normal ranges. The histopathological examination showed that vacuolar degeneration of hepatocytes at the peripheral and the middle zones of the hepatic lobules in Rotundine group, I2 and I6 groups was observed, and a small focal to a large patche of coagulative necrosis of hepatocytes occurred in the individual animals.
Table 6 Effects on transaminase in rats Dose ALT(U/L) AST(U/L) Normal control 67.0±9.8 122.0±24.6 THP 160.0±70.6* 216.8±91.6* I2 172.8±37.5* 195.0±32.1* I6 165.3±38.0* 251.8±32.0* I7 84.5±20.6 143.8±21.0 Compared with normal group, * P<0.05.
Claims (6)
- A pharmaceutical composition comprising the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt or solvate thereof as an active ingredient, and one or more suitable excipient.
- A use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt or solvate thereof in the preparation of psychotropic drug.
- A use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt or solvate thereof in the preparation of drug for the treatment of a algesic disease, such as inflammation-induced pain, cancer-induced pain, and antitumor drug-induced pain.
- A use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt or solvate thereof in the preparation of drug for the treatment of an addictive disease, such as cocaine addiction, methamphetamine addiction, opioid or drug addiction, alcohol addiction, smoking addiction, ketamine addiction.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610890151.8A CN107936008B (en) | 2016-10-13 | 2016-10-13 | Deuterated compound and medical application thereof |
PCT/CN2017/000607 WO2018068429A1 (en) | 2016-10-13 | 2017-09-22 | Deuterated derivative of l-tetrahydropalmatine and medical use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3517537A1 true EP3517537A1 (en) | 2019-07-31 |
EP3517537A4 EP3517537A4 (en) | 2020-05-27 |
EP3517537B1 EP3517537B1 (en) | 2023-09-13 |
Family
ID=61905096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17861072.1A Active EP3517537B1 (en) | 2016-10-13 | 2017-09-22 | Deuterated derivative of l-tetrahydropalmatine and medical use thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US10617679B2 (en) |
EP (1) | EP3517537B1 (en) |
JP (1) | JP7050336B2 (en) |
CN (1) | CN107936008B (en) |
WO (1) | WO2018068429A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111184719B (en) * | 2020-01-17 | 2023-02-28 | 上海交通大学 | Dopamine receptor antagonist and application thereof |
CN113354634A (en) * | 2020-03-06 | 2021-09-07 | 中国科学院化学研究所 | Compound, pharmaceutical composition containing same and application of compound in treatment of brain tumor |
CN115260185A (en) * | 2022-08-02 | 2022-11-01 | 杨征 | Deuterated derivatives of corydaline and stepholidine and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5019788A (en) * | 1973-06-25 | 1975-03-01 | ||
CN1310646C (en) * | 2002-09-18 | 2007-04-18 | 中国人民解放军军事医学科学院毒物药物研究所 | Medicinal composition containing rotundine for anayesia and giving up drug-taking |
CN102186848B (en) | 2008-09-18 | 2014-11-12 | 奥斯拜客斯制药有限公司 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
KR101054093B1 (en) * | 2008-12-05 | 2011-08-09 | 대한민국 | Drug abuse treatment containing L-THP as an active ingredient |
CN103520010A (en) * | 2013-10-18 | 2014-01-22 | 柳州两面针股份有限公司 | Application of tetrahydropalmatine and naringin in preparing oral care products |
-
2016
- 2016-10-13 CN CN201610890151.8A patent/CN107936008B/en active Active
-
2017
- 2017-09-22 JP JP2019541837A patent/JP7050336B2/en active Active
- 2017-09-22 EP EP17861072.1A patent/EP3517537B1/en active Active
- 2017-09-22 WO PCT/CN2017/000607 patent/WO2018068429A1/en unknown
-
2019
- 2019-04-12 US US16/383,307 patent/US10617679B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10617679B2 (en) | 2020-04-14 |
EP3517537A4 (en) | 2020-05-27 |
JP7050336B2 (en) | 2022-04-08 |
EP3517537B1 (en) | 2023-09-13 |
US20190240204A1 (en) | 2019-08-08 |
JP2019531353A (en) | 2019-10-31 |
CN107936008A (en) | 2018-04-20 |
CN107936008B (en) | 2022-06-14 |
WO2018068429A1 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU820659A3 (en) | Method of preparing 4-amino-5-alkylsulfonyl-o-anisamide derivatives,their salts,oxides,left-and right-rotational isomers (their variations) | |
US10617679B2 (en) | Deuterated compounds and medical uses thereof | |
JPS61225158A (en) | Phenylcarbamates | |
CN112574098B (en) | Amide compound, preparation method and application thereof | |
KR102418211B1 (en) | Inhibition of transient receptor potential A1 ion channels | |
EA020681B1 (en) | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | |
JP2651043B2 (en) | Diphenylmethylpiperazine derivative | |
RU2254330C2 (en) | Acid-additive nitrate salts of compounds and pharmaceutical composition | |
CN110872253B (en) | Lappaconitine derivative with analgesic activity and preparation method thereof | |
KR20170133493A (en) | As the A2B antagonist, xanthine-substituted alkynyl carbamate / reverse carbamate | |
US10759809B2 (en) | Deuterated compound and medical use thereof | |
JPH03141258A (en) | Novel piperazine derivative | |
KR101582429B1 (en) | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | |
JP3076672B2 (en) | Fumarate of quinoline derivative | |
EP0124208B1 (en) | Quinoline derivatives | |
US7053096B2 (en) | Compounds having selective hydrolytic potentials | |
JP2022517396A (en) | EGFR inhibitor salt, crystalline form and method for producing it | |
US10844018B2 (en) | Pyridoxine derivative for treatment of epilepsy | |
RU2675237C1 (en) | COMPOUND (6-{[(1S)-1(5-FLUORO-4-OXO-3-PHENYL-3,4-DIHYDROQUINAZOLIN-2-YL)PROPYL]AMINO}-9H-PURIN-9-YL)METHYL ACETATE AS INHIBITOR OF P110δ- DELTA ISOFORM OF PHOSPHOINOSITIDE-3-KINASE (PI3K), METHODS FOR ITS PRODUCTION (OPTIONS) AND APPLICATIONS | |
EP4043436A1 (en) | Magl inhibitor, preparation method therefor and use thereof | |
CN116891455A (en) | N-substituted phenyl-pyridazinone-3-formamide compound, preparation method and application thereof, and pharmaceutical composition | |
US4853415A (en) | 2-(substituted sulfamyl) derivatives of 4-nitrobenzamide as radiation sensitizers | |
CN112876373A (en) | Biquaternary ammonium compound and preparation method and application thereof | |
CN115108923A (en) | Trans-amantadine ammonia derivative or salt thereof, and preparation method, composition and application thereof | |
EP0270292A2 (en) | Radiation sensitizers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190424 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200423 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/34 20060101ALI20200417BHEP Ipc: A61P 25/04 20060101ALI20200417BHEP Ipc: C07D 471/04 20060101ALI20200417BHEP Ipc: A61K 31/4375 20060101ALI20200417BHEP Ipc: C07B 31/00 20060101ALI20200417BHEP Ipc: A61P 25/30 20060101ALI20200417BHEP Ipc: C07B 59/00 20060101ALI20200417BHEP Ipc: A61P 25/32 20060101ALI20200417BHEP Ipc: A61P 25/18 20060101ALI20200417BHEP Ipc: C07D 455/03 20060101AFI20200417BHEP Ipc: A61P 25/00 20060101ALI20200417BHEP Ipc: A61K 31/4745 20060101ALI20200417BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TAIZHOU HUAYUAN MEDICINAL TECH CO. LTD |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220127 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230327 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017074269 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20230913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231214 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231213 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231214 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1611217 Country of ref document: AT Kind code of ref document: T Effective date: 20230913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240113 |